Meeting
2015 Gastrointestinal Cancers Symposium
Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV.
Authors
Kazuteru Hatanaka
Department of Gastroenterology, Hakodate Municipal Hospital, Hakodate, Japan
Kazuteru Hatanaka , Satoshi Yuki , Hiroshi Nakatsumi , Hiraku Fukushima , Hirohito Naruse , Takashi Kato , Takashi Meguro , Michio Nakamura , Ichiro Iwanaga , Minoru Uebayashi , Miki Tateyama , Kazunori Eto , Mineo Kudo , Sosuke Kato , Hiroyuki Okuda , Susumu Sogabe , Kencho Miyashita , Yuh Sakata , Yoshito Komatsu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Prevention, Diagnosis, and Screening
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 527)
DOI
10.1200/jco.2015.33.3_suppl.527
Abstract #
527
Poster Bd #
A21
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
Japanese cohort study of first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC) containing fluorouracil, oxaliplatin, and bevacizumab: EMERaLD study, first report.
First Author: Keisei Taku
Poster
2012 Gastrointestinal Cancers Symposium
Phase II intermittent (or stop and go) l-OHP administration of first-line bevacizumab (BV) plus mFOLFOX6 or CapeOX therapies in Japanese patients with mCRC: The interim report of t-CORE0901.
First Author: Makio Gamoh
Poster
2024 ASCO Annual Meeting
Fruquintinib plus capecitabine versus capecitabine as first-line maintenance treatment of metastatic colorectal cancer (mCRC): Update results from the randomized, controlled, phase Ib/II study.
First Author: Wenhua Li
Poster
2023 ASCO Annual Meeting
Impact of sex on the efficacy of first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus Y90-radioembolization in patients with metastatic colorectal cancer: An exploratory, retrospective analysis of the phase III SIRFLOX trial.
First Author: Kathrin Heinrich